← All candidates
One insider buy in the last year — $10.6K in all.
39 filings on record.
KROSKeros Therapeutics, Inc.
NasdaqGM · Healthcare · $217.90M
$11.17
-0.36% · Sep 15
One insider buy in the last year — $10.6K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 17 sells◆ 8 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$217.90M
Float
17.8M
90% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
14.5
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Bienaime Jean Jacques
Bought $10.6K on May 15 — 1,000 sh @ $10.58, held direct, 11% of their stake.
1 of 1 position beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
34 more transactions on Pro →Context
Wall St
$21.83 avg target
+95.5% vs today · 6 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$1.21 act−$0.29
Q4 '25−$0.86 act−$0.41
Q3 '25−$0.18 act+$0.74
Q2 '25−$0.76 act+$0.37
Coverage
KROS Turns to Next Wave of TGF-Beta Muscle TherapiesZacks · 05-22Should You Buy KROS After Q1 Miss and Takeda Deal Reset?Zacks · 05-22KROS Stock Guide to Rinvatercept in DMD and ALS for 2026Zacks · 05-22Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20Simply Wall St. · 05-17
The file stays open
39 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice